Compare Organon & Co. Common Stock (OGN) vs Schlumberger NV (SLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Schlumberger NV — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while Schlumberger NV trades at $48.63 (market cap $72.38B). The key difference: Schlumberger NV is far larger — about 20× Organon & Co. Common Stock's market cap, and Schlumberger NV pays the higher dividend (2.42%). Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Schlumberger NV for 99 Days on average.
| OGN | SLB | |
|---|---|---|
Market Cap | $3.62B | $72.38B |
Volume | 2,892,999 | 10,231,115 |
Sector | Health | Energy |
52-Week High | $13.81 | $60.10 |
52-Week Low | $5.70 | $32.57 |
Typical Hold Time | 0 Days | 99 Days |
Enterprise Value | $11.04B | $81.11B |
Dividend Yield | 0.58% | 2.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
SLB trades at $48.51, down 0.53% on the day, with a bearish technical signal from moving averages. The company maintains strong profitability with 8.53% net income margin and 13.37% ROE, though revenue declined slightly to $35.71B in 2025. Recent contract wins in Saudi Arabia, Oman, and Mozambique provide multi-year revenue visibility. Analyst consensus remains strongly bullish with 85% buy ratings and $64.58 price target representing 33% upside potential.
SLB presents a compelling value opportunity with solid fundamentals and strong analyst support, though near-term headwinds include declining profit margins and bearish technical indicators. The company's recent major contract awards and dividend payments provide stability, but investors should monitor execution risks in international markets and potential volatility in energy sector demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Schlumberger NV
Schlumberger is the largest oilfield service firm in the world, with expertise in myriad disciplines, including reservoir performance, well construction, production enhancement, and more recently, digital solutions. It maintains a reputation as one of the industry's leading innovators, which has earned it dominant share in numerous end markets.
Read more on SLB →
